Introduction
Relapsing polychondritis is treated with anti-inflammatory and immunosuppressive therapies, along with procedures that support damaged cartilage or affected organs when necessary. Because the condition is driven by immune-mediated inflammation against cartilage and related connective tissues, treatment is aimed not only at relieving pain and swelling but also at suppressing the abnormal immune response that causes tissue destruction. In milder disease, treatment may focus on controlling localized inflammation; in more severe or systemic disease, stronger medications are used to prevent airway compromise, hearing loss, joint damage, or other complications.
The overall strategy is to reduce active inflammation, limit further cartilage injury, preserve structure and function in vulnerable tissues, and manage complications that result from chronic inflammation or mechanical weakening of cartilage. The choice of therapy depends on which tissues are involved, how aggressive the disease is, and how the body responds over time.
Understanding the Treatment Goals
The main goals of treatment in relapsing polychondritis reflect the biology of the disease. The first goal is to reduce symptoms such as pain, redness, swelling, stiffness, and fever by suppressing inflammatory activity in affected cartilage and surrounding tissues. A second goal is to address the underlying immune process, which in many cases appears to involve autoimmunity against cartilage components such as type II collagen and associated matrix proteins. By lowering immune activation, treatment can reduce recurrent attacks and tissue injury.
A third goal is to prevent progression. Repeated inflammation can weaken cartilage, leading to deformity of the ears, collapse of the nasal bridge, narrowing of the airways, or damage to the voice box and eyes. Treatment is designed to interrupt this cycle before structural damage becomes fixed. A fourth goal is restoration of function, especially in structures where cartilage provides support and shape, such as the trachea, bronchi, nose, and external ear. Finally, treatment aims to reduce complications from both the disease and the therapies themselves, since long-term immunosuppression carries its own risks.
These goals guide treatment decisions because relapsing polychondritis can range from limited, intermittent inflammation to severe multisystem disease. A therapy that is sufficient for isolated auricular inflammation may be inadequate when the airway, heart valves, or eyes are involved. In practice, treatment intensity follows the expected threat to function and the likelihood of ongoing immune activity.
Common Medical Treatments
Corticosteroids are often the first-line treatment for active relapsing polychondritis. Drugs such as prednisone work by broadly suppressing inflammatory gene expression, reducing cytokine production, limiting leukocyte migration into tissues, and stabilizing cell membranes. This decreases the swelling and immune-cell infiltration that damage cartilage. Corticosteroids are especially useful during flares because they act relatively quickly compared with other immunosuppressive agents. Their main target is the acute inflammatory phase of the disease, particularly when the airway, eyes, or cardiovascular structures are at risk.
Nonsteroidal anti-inflammatory drugs may be used in milder disease or as adjunctive therapy for pain and inflammation. They inhibit cyclooxygenase enzymes and reduce prostaglandin synthesis, which lowers local inflammation and pain signaling. These drugs help with symptom control, but they do not meaningfully suppress the autoimmune process driving cartilage destruction. For that reason, they are usually insufficient as sole therapy when disease is systemic or progressive.
Conventional immunosuppressive agents are used when corticosteroids are inadequate, when steroid-sparing treatment is needed, or when disease is recurrent. Methotrexate is commonly used and acts by interfering with folate-dependent pathways and increasing anti-inflammatory adenosine signaling, which reduces immune-cell proliferation and inflammatory activity. Azathioprine and mycophenolate mofetil suppress lymphocyte expansion by interfering with nucleotide synthesis, limiting the adaptive immune response that sustains recurrent cartilage inflammation. Cyclophosphamide, a more intensive agent, suppresses rapidly dividing immune cells and may be used in severe or life-threatening disease. These treatments target the underlying immune activation rather than only symptom relief, which makes them useful for chronic disease control.
Dapsone has been used in some patients with inflammatory or neutrophil-predominant features. Its effects include suppression of neutrophil-mediated inflammation and oxidative tissue injury. Because neutrophils can contribute to cartilage inflammation in relapsing polychondritis, this mechanism may help in selected cases, although responses vary.
Biologic therapies are increasingly used when disease is refractory. Tumor necrosis factor inhibitors, such as infliximab or adalimumab, block a cytokine that amplifies inflammation, leukocyte recruitment, and tissue injury. Other biologics target interleukin pathways or B-cell activity, depending on the dominant inflammatory mechanism suspected in a given case. For example, rituximab reduces B cells, which can lower autoantibody production and antigen presentation. Tocilizumab blocks the interleukin-6 receptor, reducing a cytokine linked to systemic inflammation and acute-phase responses. These drugs are designed to disrupt specific immune signals rather than suppress immunity in a broad, nonspecific way, which can be useful when standard agents fail.
Colchicine may occasionally be used for milder inflammatory disease or overlap with other inflammatory disorders. It disrupts microtubule assembly and reduces neutrophil motility and activation. Its benefit comes from damping a subset of inflammatory pathways rather than altering the core autoimmune process. For that reason, it is generally less central than corticosteroids or conventional immunosuppressants.
Procedures or Interventions
Procedures are used when inflammation has caused structural damage or when specific organs are endangered by cartilage failure. The most important intervention is often related to the airway. In relapsing polychondritis, inflammation can weaken the cartilaginous rings of the trachea and bronchi, allowing dynamic airway collapse. When this occurs, interventions such as tracheostomy, airway stenting, or ventilatory support may be required. These procedures do not treat the immune disease itself; instead, they mechanically stabilize the airway or bypass the weakened segment, preserving ventilation when cartilage can no longer maintain lumen patency.
Surgical reconstruction may be considered for severe nasal saddle deformity or for functional problems related to collapsed cartilage. Such procedures restore structure, but they are usually more effective after inflammation is controlled, because active immune-mediated destruction can compromise surgical results. In that sense, surgery addresses the anatomical consequence of the disease rather than the inflammatory cause.
If the eyes are involved, local ophthalmologic interventions may be used to control inflammatory damage, depending on the exact site of involvement. Similarly, if the heart valves or great vessels are affected, cardiology-directed procedures may be necessary when inflammation leads to fixed structural changes such as valvular insufficiency or aneurysmal disease. These interventions are reserved for complications of long-standing inflammation, not for routine disease control.
Supportive or Long-Term Management Approaches
Long-term management in relapsing polychondritis depends on repeated assessment of disease activity and organ involvement. Because the illness often follows a relapsing course, ongoing monitoring is important for detecting changes in airway function, hearing, ocular inflammation, joint symptoms, or cardiovascular involvement before permanent damage develops. This follow-up is not merely surveillance; it helps match treatment intensity to the current degree of immune activity and tissue injury.
Maintenance therapy often uses lower doses of corticosteroids combined with steroid-sparing immunosuppressants. This approach reduces cumulative steroid exposure while still suppressing pathogenic immune pathways. Over time, the biological aim is to keep inflammatory signaling below the threshold that produces cartilage destruction. In recurrent disease, long-term suppressive therapy can prevent repeated cycles of swelling, matrix breakdown, and scarring.
Supportive management also includes treatment of complications from chronic disease. Hearing loss may require audiologic evaluation and assistive devices if inflammation has damaged auricular or inner-ear structures. Airway disease may require serial imaging or pulmonary function assessment to measure collapse or narrowing. These measures do not modify immune activity directly, but they help quantify the physiological impact of the disease and guide timely intervention.
In people taking immunosuppressive therapy, long-term management involves monitoring for infection, blood count abnormalities, liver injury, kidney dysfunction, and other treatment-related effects. This reflects the trade-off inherent in suppressing a harmful immune response: the same mechanisms that reduce tissue injury can also reduce host defense or affect rapidly dividing normal cells.
Factors That Influence Treatment Choices
Treatment choice depends first on severity and organ involvement. Limited auricular or nasal inflammation may respond to less intensive therapy, while airway, ocular, cardiac, or neurologic involvement usually requires rapid and stronger immunosuppression. Severe disease suggests a higher risk of irreversible structural damage, so the threshold for systemic therapy is lower. The stage of disease also matters: active inflammatory flares are treated more aggressively than quiescent periods, and chronic deformity may require procedural support rather than anti-inflammatory therapy alone.
Age and general health influence how much immunosuppression can be tolerated. Older patients or those with comorbidities may be more vulnerable to infection, osteoporosis, glucose intolerance, or medication toxicity from corticosteroids and other immunosuppressants. Kidney or liver disease can limit the use of certain agents because many are metabolized or cleared through those organs. The presence of related autoimmune disease can also affect treatment selection, since overlapping immune disorders may alter the expected response to a particular drug class.
Response to previous treatment is another major determinant. Some patients respond well to corticosteroids and remain stable on a steroid-sparing agent. Others relapse when steroid doses are reduced, which suggests persistent immune activation that requires stronger maintenance therapy. Refractory disease often leads to biologic treatment, especially if standard immunosuppressants fail to control inflammation or if toxicity limits their use. Thus, treatment is often escalated stepwise according to biologic response rather than according to a fixed sequence.
Potential Risks or Limitations of Treatment
The main limitation of treatment is that no therapy reliably cures the underlying autoimmune tendency. Most medications suppress inflammation rather than eliminate the immune process entirely, so relapses can still occur. This chronicity is a consequence of the disease biology: cartilage remains a target tissue, and immune memory can sustain recurring inflammatory episodes.
Corticosteroids are effective but have well-known dose-related adverse effects. By altering glucose metabolism, bone turnover, fluid balance, and immune function, they can cause hyperglycemia, osteoporosis, hypertension, mood changes, weight gain, infection risk, and tissue thinning. These effects arise because corticosteroids influence many physiological systems beyond inflammation. Their usefulness in acute control must therefore be balanced against toxicity, especially with prolonged use.
Immunosuppressive drugs can cause bone marrow suppression, liver toxicity, kidney effects, gastrointestinal symptoms, and increased susceptibility to infection. These risks result from their impact on rapidly dividing immune cells and, in some cases, other proliferating tissues. Biologic therapies may also increase infection risk and can cause infusion reactions, injection-site reactions, or paradoxical immune effects. Because they target specific signaling pathways, they can alter host defense in ways that are not immediately obvious.
Procedures also have limitations. Airway stents can migrate, become obstructed, or provoke local irritation and granulation tissue. Surgery performed during active inflammation may heal poorly or fail over time if the disease remains active. Mechanical interventions are therefore best viewed as supportive measures for structural failure, not substitutes for immunologic control.
Conclusion
Relapsing polychondritis is treated through a combination of anti-inflammatory drugs, immunosuppressive therapy, biologic agents, and, when necessary, procedures that stabilize damaged structures or correct complications. Corticosteroids provide rapid suppression of acute inflammation, conventional immunosuppressants and biologics aim to reduce the immune mechanisms that drive recurrent cartilage injury, and procedures address the mechanical consequences of cartilage destruction, especially in the airway and nose. Long-term management depends on repeated assessment, maintenance immunosuppression when needed, and monitoring for both disease progression and treatment toxicity.
The central principle of treatment is to interrupt the cycle of immune-mediated inflammation that progressively weakens cartilage and associated tissues. By lowering inflammatory signaling, limiting immune-cell activity, and preserving organ structure, treatment seeks to maintain function and reduce the risk of irreversible complications.